Director Share Purchase

RNS Number : 6804T

Tissue Regenix Group PLC

22 November 2013

 



Tissue Regenix Group plc

Director Share Purchase

YORK, 22 November 2013 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the international regenerative medical devices company, has received notification that on 21 November 2013, John Samuel, Executive Chairman of the Group, purchased 148,000 ordinary shares of 0.5 pence at a price of 13.5 pence per share.

Following this purchase, Mr Samuel has an interest in the Group of 13,536,928 ordinary shares and a beneficial interest in a further 10,740,000 ordinary shares, in total representing 3.7% of the issued share capital of the Group. 

ENDS

For Further Information

Tissue Regenix Group Plc:                                                           [phone]

Antony Odell

Ian Jefferson

Jefferies International Ltd:                                                         [phone]

Simon Hardy

Harry Nicholas

Newgate Communications:                                                        [phone]

Alistair Kellie                                                                                   

Andrew Jones                                                                  

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

 

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

 

END

 

 

RDSFEWFWFFDSEEF